Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this... see more

Recent & Breaking News (NDAQ:CRSP)

CRISPR Therapeutics Announces Proposed Offering of Common Shares

GlobeNewswire June 29, 2020

CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility

GlobeNewswire June 25, 2020

CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001(TM) in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress

GlobeNewswire June 12, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire May 26, 2020

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting

GlobeNewswire May 15, 2020

New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001(TM) for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress

GlobeNewswire May 14, 2020

CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001(TM) for the Treatment of Severe Hemoglobinopathies

GlobeNewswire May 11, 2020

CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference

GlobeNewswire May 7, 2020

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results

GlobeNewswire April 28, 2020

CRISPR Therapeutics Proposes Changes to the Board of Directors

GlobeNewswire February 26, 2020

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 12, 2020

CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference

GlobeNewswire January 6, 2020

CRISPR Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 27, 2019

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

GlobeNewswire November 20, 2019

CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

GlobeNewswire November 19, 2019

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

GlobeNewswire November 19, 2019

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results

GlobeNewswire October 28, 2019

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies' Respective Cell Therapy Programs in Oncology

GlobeNewswire October 15, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire October 1, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire July 31, 2019